Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to
vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis
(AIK). Participants will return for a follow up visit 1 week after end of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Invirsa, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority